These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25609335)

  • 1. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
    Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
    J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
    Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ecallantide in pediatric hereditary angioedema.
    MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
    Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
    Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema.
    Stolz LE; Horn PT
    Drugs Today (Barc); 2010 Aug; 46(8):547-55. PubMed ID: 20830315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
    Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
    Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema.
    Stolz LE; Sheffer AL
    Expert Rev Clin Immunol; 2012 Jan; 8(1):25-32. PubMed ID: 22149337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
    Banta E; Horn P; Craig TJ
    Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ecallantide for the treatment of acute attacks in hereditary angioedema.
    Cicardi M; Levy RJ; McNeil DL; Li HH; Sheffer AL; Campion M; Horn PT; Pullman WE
    N Engl J Med; 2010 Aug; 363(6):523-31. PubMed ID: 20818887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ecallantide for treatment of acute attacks of hereditary angioedema.
    Martello JL; Woytowish MR; Chambers H
    Am J Health Syst Pharm; 2012 Apr; 69(8):651-7. PubMed ID: 22472866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response time for ecallantide treatment of acute hereditary angioedema attacks.
    Riedl M; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):430-436.e2. PubMed ID: 21130380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
    Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
    Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
    Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
    Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
    J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
    MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
    Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ecallantide: in acute hereditary angioedema.
    Garnock-Jones KP
    Drugs; 2010 Jul; 70(11):1423-31. PubMed ID: 20614949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability.
    Bernstein JA; Qazi M
    Expert Rev Clin Immunol; 2010 Jan; 6(1):29-39. PubMed ID: 20383888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies.
    Sheffer AL; Campion M; Levy RJ; Li HH; Horn PT; Pullman WE
    J Allergy Clin Immunol; 2011 Jul; 128(1):153-159.e4. PubMed ID: 21481442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immediate hypersensitivity reactions to corticosteroids.
    Patel A; Bahna SL
    Ann Allergy Asthma Immunol; 2015 Sep; 115(3):178-182.e3. PubMed ID: 26211812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.